In conclusion, the enhanced expression of INHA or INHBB detected in 80% of our HCC patients may serve as alternative or additional regulators besides follistatin, fstl3 and cripto, overriding the antiproliferative and proapoptotic action of activin A. Here, INHA is linked to hepatocellular carcinoma.